Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs... Show more
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology
A.I.dvisor indicates that over the last year, CAPR has been loosely correlated with ENLV. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CAPR jumps, then ENLV could also see price increases.
| Ticker / NAME | Correlation To CAPR | 1D Price Change % | ||
|---|---|---|---|---|
| CAPR | 100% | -1.61% | ||
| ENLV - CAPR | 39% Loosely correlated | -5.75% | ||
| PHVS - CAPR | 37% Loosely correlated | -0.56% | ||
| VRAX - CAPR | 33% Loosely correlated | -5.11% | ||
| WVE - CAPR | 33% Loosely correlated | -0.82% | ||
| KRRO - CAPR | 33% Poorly correlated | +0.53% | ||
More | ||||
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CAPR declined for three days, in 249 of 299 cases, the price declined further within the following month. The odds of a continued downward trend are 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on CAPR as a result. In 72 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
CAPR moved above its 50-day moving average on September 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on September 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 138 of 168 cases where CAPR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. CAPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.057) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.